MaxCyte Future Growth

Future criteria checks 1/6

MaxCyte's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 19.3% per year. EPS is expected to decline by 1.2% per annum. Return on equity is forecast to be -18.8% in 3 years.

Key information

-1.9%

Earnings growth rate

-1.2%

EPS growth rate

Life Sciences earnings growth	21.8%
Revenue growth rate	19.3%
Future return on equity	-18.8%
Analyst coverage	Good
Last updated	08 May 2024

Recent future growth updates

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Recent updates

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

If You Had Bought MaxCyte (LON:MXCT) Shares A Year Ago You'd Have Earned 249% Returns

Nov 24

Earnings and Revenue Growth Forecasts

AIM:MXCT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	65	-34	-47	-27	3
12/31/2025	47	-45	-58	-33	8
12/31/2024	36	-49	-59	-40	8
3/31/2024	44	-37	-31	-28	N/A
12/31/2023	41	-38	-25	-22	N/A
9/30/2023	38	-37	-34	-29	N/A
6/30/2023	41	-33	-34	-26	N/A
3/31/2023	41	-30	-29	-15	N/A
12/31/2022	44	-24	-33	-15	N/A
9/30/2022	42	-24	-27	-10	N/A
6/30/2022	41	-20	-20	-4	N/A
3/31/2022	39	-16	-19	-10	N/A
12/31/2021	34	-19	-15	-11	N/A
9/30/2021	32	-17	-15	-12	N/A
6/30/2021	29	-17	-14	-12	N/A
3/31/2021	27	-16	-10	-8	N/A
12/31/2020	26	-12	-11	-9	N/A
9/30/2020	24	-11	-10	-8	N/A
6/30/2020	24	-9	-10	-8	N/A
3/31/2020	23	-11	-13	-11	N/A
12/31/2019	22	-13	-10	-9	N/A
9/30/2019	20	-13	-11	-10	N/A
6/30/2019	18	-14	-11	-10	N/A
3/31/2019	17	-11	-11	-10	N/A
12/31/2018	17	-9	-11	-10	N/A
9/30/2018	16	-10	-11	-11	N/A
6/30/2018	15	-10	-12	-11	N/A
3/31/2018	14	-10	-11	-10	N/A
12/31/2017	14	-10	N/A	-10	N/A
9/30/2017	13	-8	N/A	-8	N/A
6/30/2017	13	-6	N/A	-6	N/A
3/31/2017	13	-5	N/A	-4	N/A
12/31/2016	12	-4	N/A	-2	N/A
9/30/2016	11	-4	N/A	-2	N/A
6/30/2016	11	-3	N/A	-2	N/A
3/31/2016	10	-3	N/A	-1	N/A
12/31/2015	9	-4	N/A	0	N/A
9/30/2015	9	-4	N/A	0	N/A
6/30/2015	8	-4	N/A	0	N/A
3/31/2015	8	-4	N/A	-1	N/A
12/31/2014	7	-4	N/A	-2	N/A
12/31/2013	7	-3	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MXCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MXCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MXCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MXCT's revenue (19.3% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: MXCT's revenue (19.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MXCT is forecast to be unprofitable in 3 years.

MaxCyte Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Recent updates

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

Consensus estimates of losses per share improve by 16%

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021